Lexicon Pharmaceuticals (LXRX) Reports Mixed Q4 Results
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.64 --0%
EPS Growth %: -600.0%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
DTGI, CRMT, STZ, More
EPS Growth %: -600.0%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
DTGI, CRMT, STZ, More
Join SI Premium – FREE
Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q4 EPS of ($0.10), $0.02 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $343 thousand versus the consensus estimate of $290 thousand.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
- UnitedHealth Group (UNH) PT Raised to $468 at Morgan Stanley
- AeroVironment (AVAV) Tops Q4 EPS by 36c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
